Navigation Links
Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.

PRINCETON, N.J., Jan. 31, 2011 /PRNewswire/ -- Laureate Pharma, Inc. has changed its name to Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma) to better describe the company's positioning in the biopharmaceutical industry.  The company's logo has been updated to emphasize "Laureate" and to incorporate a laurel wreath, illustrating Laureate Biopharma's reputation for scientific excellence and commitment to delivery.  In addition, the company has established a new homepage (  

Laureate Biopharma has been in continuous operation in its Princeton, New Jersey facility since 1981.  Since 1996, Laureate Biopharma has focused exclusively on serving other developers in the biotherapeutics market.  

"We are building on Laureate Biopharma's rich history and adding technologies, capacity and staff, while extending our reputation for quality and delivery," said Michael A. Griffith, Chief Executive Officer.  "This name change, although subtle, speaks to our wealth of experience in protein production and a deep scientific bench, which is unique to the industry."

This name change follows the company's announcement of $20 million in secured capital.  All strategically planned improvements are continuing as previously announced.  These include:

  • Adoption of new quality systems technologies
  • Upgrade of aseptic fill capabilities
  • Upgrade and expansion of protein production facilities and services
  • Expansion of mammalian cell line creation services, and
  • Launch of a contract analytical testing business

For more information related to Laureate Biopharma's capabilities and ongoing improvements please visit them at their new website,  

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharmaceutical Services, at (609) 919-3367, or or visit or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
2. Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals Antibody Therapeutic
3. Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research
4. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
5. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
6. Thomson Reuters Predicts Nobel Laureates
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
9. Vanda Pharmaceuticals Files Shelf Registration Statement
10. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
11. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):